Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.37 | $-0.91 | -44.51% |
| Revenue | N/A | $0M | N/A |
management commentary, guidance changes, and full analysis available with Pro.
Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders....
EPS
Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue
While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.
Wall Street expectations, options signals, track record, and call prep available with Pro.
| EPS | $-1.37 | $-0.91 | -44.51% |
| Revenue | N/A | $0M | N/A |
Tone: Unknown
No transcript is on record, and the analysis is based on numerical results only.
Viking Therapeutics reported a larger-than-expected loss per share, which contributed to a 3.27% decline in its stock price. The lack of revenue and guidance further adds uncertainty for investors. Overall, the disappointing EPS results may raise concerns about the company's financial health moving forward.
EPS Beat Streak
0Q
EPS Beat Rate
25%
Avg EPS Surprise
-19.44%
Avg Stock Reaction
-0.60%
In the last quarter, Viking Therapeutics reported an EPS of $-1.38, missing the estimate of $-0.89. The stock reacted negatively, declining by 0.70% the following day.
Management Promises & Guidance
Analysts expect Viking to report a loss this quarter, with a consensus EPS of $-0.91. Given the company's history of missing earnings expectations, there is a cautious sentiment among investors.
Bull Case
If Viking can narrow its losses significantly or provide positive updates on its drug pipeline, it could boost investor confidence and lead to a positive stock reaction.
Bear Case
Conversely, if the company reports a larger loss than expected or fails to provide any new insights into its future revenue potential, it could lead to further declines in the stock price.
EPS
$-0.91Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue
$0MWhile no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.
Expectations
The print will turn on these two things.
Q1
Will Viking provide any updates on its drug pipeline that could signal future revenue potential?
Investors are keen to understand how the company plans to generate revenue, especially given the lack of expected revenue this quarter.
Q2
How does Viking plan to address its ongoing losses, and what steps are being taken to improve profitability?
Management's response to profitability concerns will be critical for investor confidence and could influence stock performance.
Edge
Why consensus could be wrong
The Street may be overly pessimistic about Viking's potential for revenue generation, especially if there are positive developments in its drug pipeline that have not been fully accounted for.
Supporting Evidence
The options market is pricing in an 8.67% move, indicating expectations of volatility that may not align with the actual performance.
Viking's historical performance shows a tendency to surprise on the upside, even when consensus is cautious.
Key Risk
If Viking provides any positive updates on its drug pipeline or plans for future revenue, it could significantly shift market sentiment.
Edge
Pre-commit to what would confirm each case.
The core debate this quarter revolves around the company's ability to manage its losses and provide a clear path to future profitability.
Bull Confirmed If
A narrower loss than the consensus estimate of $-0.91 could confirm a more optimistic outlook.
Bear Confirmed If
A larger loss than expected, particularly if it exceeds $-1.43, would reinforce bearish sentiment.
Pre-Earnings Positioning
Implied Move
±8.67%
Historical Avg
±2.8%
The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.
Options are pricing ±8.5% while VKTX has averaged ±2.8% over the last 8 prints — setup is pricing rich.
ATM IV
1.4%
30d HV
53.3%
Edge
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich setup in Health Care
n=30Fade rate: 11 of 25 (44%)
This setup has occurred 30 times across Health Care in the last 2 years. 11 of 25 faded and 14 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.3%, with a raw directional average of +2.3% (modestly positive historical bias).
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Viking beats expectations and narrows its losses, history suggests the stock could rise by an average of 1.54% the next day.
In-Line / Cautious
If results are in line with expectations, management's commentary could lead to a muted response, reflecting cautious sentiment.
Miss
If the company misses expectations, history suggests a potential decline of about 0.67% the following day.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Polaris Inc.